Key facts
- Promaxo’s last known valuation is $104.2M (Jan 2021).
- It has raised $107.7M across 3 recorded rounds; the latest was Early Stage VC ($41.9M) in Mar 2024.
- Notable investors include US National Science Foundation, MedTech Innovator, Keiretsu Forum, TEDCO, Band of Angels — 24 tracked in total.
- Promaxo has filed 4 Form Ds with the SEC since 2020, most recently Jul 2024 ($41.9M sold to 163 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Promaxo
Funding rounds
3 roundsAbout Promaxo
Developer of a portable magnetic resonance imaging (MRI) system designed for improving prostate cancer diagnosis and treatment. The company's system integrates imaging, artificial intelligence, and robotics, offering features such as real-time intra-operative planning, targeted interventions, and compact installation, enabling healthcare providers to enhance diagnostic accuracy, streamline procedures, and deliver personalized care in accessible settings.
- Sector
- Healthcare
- HQ
- Oakland, CA, United States
- Founded
- 2016
- Employees
- 58
- Website
- promaxo.com/
- Ownership
- Privately Held (backing)
Promaxo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Promaxo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Promaxo in its N-PORT filings yet. We sweep new filings monthly.